Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Once-weekly taspoglutide was superior to twice-daily ... and hypersensitivity reactions. Clearly, GLP-1 receptor agonists may not be appropriate for all patients with type 2 diabetes, as they ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months ... loss come as shots that users give ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

Catherine E Murphy PharmD BCPS BCACP, Assistant Professor, Albany College of Pharmacy & Health Sciences, Colchester, VT ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

It could be used less frequently (once monthly) than the current once-weekly GLP-1 injectables. It also has a similar weight-loss profile to the current market leaders. It's already in phase II ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...